drugset / Trial / NCT00392756

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756

Phase 1 Completed 624 enrolled Massachusetts General Hospital
Non-randomizedSingle-groupOpen-labelOther

Summary

The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain called the hypothalamus. When GnRH is released, it signals another gland in the brain, the pituitary, to secrete the reproductive hormones that influence sex hormone (testosterone, estrogen) levels and gamete (sperm, egg cell) production. This study involves a detailed evaluation and 24-48 hours stay at the hospital. In this study, males and females ages 16 and older with IHH have a detailed evaluation which involves an overnight study at the hospital. Some men (18 years and older) may continue on to receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in IHH and results in normalized testosterone and typically is effective in developing fertility.

Timeline

Start
1989-04
Primary completion
2019-05-16
Completion
2019-05-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gonadorelin Protein / enzyme biologic 0.025 ug/kg Subcutaneous

Indications